1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
REGENXBIO Inc.

REGENXBIO Inc.

RGNX
REGENXBIO Inc.US flagNASDAQ Global Select
6.66
USD
+0.38
- -
344.31MMarket Cap
REGENXBIO Inc.
RGNX
(NASDAQ Global Select)

Recent

price

6.66

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.46
0.47
0.83
0.17
0.35
6.54
0.96
4.15
11.08
2.61
2.06
1.68
3.3
1.69
Revenue per Share
-0.44
-0.37
-2.68
-2.38
-2.45
2.99
-2.58
-2.98
3.01
-6.5
-6.02
-4.59
-3.76
-5.59
Basic EPS, GAAP
-0.23
-0.18
-2.51
-2.15
-2.18
2.73
-3.25
-2.17
3.17
-5.52
-5.22
-3.55
-2.45
-4.56
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.06
-2.19
-5.63
-4.34
-6.28
-2.48
-4.85
-7.75
-3.8
-10.23
-16.12
-18.83
-21.83
-23.46
Book Value per Share
-1.06
-1.39
23.64
6.12
6.13
15.22
12.27
10.13
18.01
11.96
7.13
5.24
1.99
0.41
Tangible Book Value per Share
13
13
9
26
30
33
37
37
42
43
44
50
52
52
Basic Weighted Avg Shares
6
6
8
5
10
219
35
155
470
113
90
83
170
88
Sales/Revenue/Turnover
-78.23
-60.16
-304.92
-1,423.84
-730.15
40.32
-422.89
-77.14
34.01
-233.2
-297.12
-277.51
-94.58
-292.28
Operating Margin (%)
- -
- -
- -
1
3
4
7
8
10
13
17
16
16
16
Depreciation Expense
-5
-4
-23
-63
-73
100
-95
-111
128
-280
-263
-227
-194
-290
Net Income, GAAP
- -
- -
- -
- -
- -
4.01
- -
- -
9.49
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-88.5
-65.41
-300.62
-1,372.13
-704.02
45.74
-268.88
-71.98
27.18
-248.68
-291.99
-272.54
-113.75
-330.23
Profit Margin (%)
-2
-6
114
84
154
316
311
450
388
286
205
175
163
115
Working Capital
- -
- -
- -
- -
- -
6
9
70
85
89
82
74
65
63
LT Debt
-2
-6
217
162
183
509
450
378
764
516
312
260
103
21
Total Equity
- -
- -
- -
- -
- -
24.21
- -
- -
22.01
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-75.45
- -
- -
-104.22
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
9
8
8
LT Borrowings
- -
- -
- -
LT Finance Leases
67
65
63
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
52
Market Capitalization
496
743
434

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
332
281
187
Cash, Cash Equivalents & STI
274
230
150
Accounts Receivable, Net
- -
1
3
Inventories
- -
- -
- -
Total Current Liabilities
125
118
71
Payables & Accruals
46
42
34
ST Debt
9
8
8
Deferred Revenue
13
10
6

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.13%
-9.38%
-60.43%
Free Cash Flow
-94.07%
-119.71%
-28.02%
Net Income, GAAP
-79.03%
-113.72%
-14.63%
Sales/Revenue/Turnover
254.94%
41.04%
104.54%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16
22
24
21
83
2025
89
21
30
30
170
2026
6
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.38
-1.05
-1.17
-1.01
-4.59
2025
0.12
-1.38
-1.2
-1.3
-3.76
2026
-1.72
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Idorsia Ltd (0RQE.L)
Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ)
SkinBioTherapeutics Plc (SBTX.L)
OnKure Therapeutics, Inc. (OKUR)
Aptose Biosciences Inc. (APS.TO)
Recce Pharmaceuticals Ltd (RCE.AX)
Business
REGENXBIO Inc. (Nasdaq: RGNX) is a clinical-stage biotechnology company that develops, commercializes, and licenses recombinant adeno-associated virus (rAAV) gene therapies for the treatment of rare and debilitating diseases. The company offers a broad pipeline of product candidates across diverse therapeutic areas, including ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy via suprachoroidal delivery, RGX-121 for the treatment of Hunter syndrome (MPS II), RGX-202 for the treatment of Duchenne muscular dystrophy, and RGX-111 for the treatment of fragile X syndrome; it also provides its NAV Technology platform, which licenses proprietary rAAV vectors and capsids to partners such as AbbVie, Novartis, and Sarepta Therapeutics for use in their gene therapy programs. Founded in 2008 and headquartered in Rockville, Maryland, REGENXBIO operates primarily in the United States with a focus on ophthalmology, neurodegeneration, and metabolic diseases, targeting patients with unmet medical needs in rare genetic disorders. In recent developments, REGENXBIO reported positive 2-year data from its Phase I/II AFFINITY trial of ABBV-RGX-314 in patients with advanced wet AMD, demonstrating sustained vision preservation and reduction in anti-VEGF treatment burden. The company also advanced its RGX-121 program with FDA clearance of an investigational new drug application and initiation of the pivotal INSPIRE trial in 2024, alongside dosing the first pediatric patient. Additionally, REGENXBIO expanded its collaboration with AbbVie through a new license agreement for novel AAV capsids and strengthened its manufacturing capabilities with the completion of a state-of-the-art gene therapy facility in 2024 to support commercial-scale production.

Company News

MCPAPIChat

  • seekingalpha.com

    REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

  • prnewswire.com

    REGENXBIO to Participate in Upcoming Investor Conferences

  • seekingalpha.com

    REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript

  • benzinga.com

    REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval

  • zacks.com

    Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates

  • prnewswire.com

    REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

  • reuters.com

    Regenxbio's muscle disorder therapy meets main goal in late-stage study

  • prnewswire.com

    REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202

  • prnewswire.com

    REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

  • prnewswire.com

    REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

  • prnewswire.com

    REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

  • prnewswire.com

    RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

  • newsfilecorp.com

    Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • businesswire.com

    RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

  • businesswire.com

    CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026

  • globenewswire.com

    Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors

  • prnewswire.com

    RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm

  • newsfilecorp.com

    Faruqi & Faruqi, LLP Highlights Class Action Against REGENXBIO (RGNX) and Upcoming Lead Plaintiff Deadline of April 14, 2026

  • newsfilecorp.com

    REGENXBIO DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNX

  • globenewswire.com

    Levi & Korsinsky, LLP: RGNX Disclosure Timeline Reveals Pattern of Alleged Investor Harm